Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL22265893 | 1.00 | HIF1A (0.56) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 | |
| Bromide SCHEMBL20541910 | 1.00 | HIF1A (0.56) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 | |
| Bromide SCHEMBL4207555 | 1.00 | HIF1A (0.56) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 | |
| Bromide SCHEMBL20541311 | 1.00 | HIF1A (0.56) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 | |
| Bromide SCHEMBL18729719 | 1.00 | HIF1A (0.56) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 | |
| Bromide SCHEMBL20541756 | 1.00 | HIF1A (0.56) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 | |
| Bromide SCHEMBL23883184 | 0.98 | HIF1A (0.54) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 | |
| Bromide SCHEMBL2552372 | 0.98 | HIF1A (0.54) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 | |
| Bromide SCHEMBL2552373 | 0.98 | HIF1A (0.54) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30872528 | 0.98 | HIF1A (0.54) | HIF1AHRH1HTR2ACHRNA7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035504-A1 | POLYMER AND USE THEREOF | SHENZHEN SENIOR TECHNOLOGY MATERIAL CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4626900-A1 | PORPHYRIN AND PHOSPHONIUM-PORPHYRIN BASED COMPOUNDS FOR PHOTODYNAMIC THERAPY AND DIAGNOSTICS | RMW Cho Group Limited (HK) | 2025-10-08 | — | — | EP | disclosed |
| US-20250177533-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | Invion Limited (AU) | 2025-06-05 | — | — | US | disclosed |
| US-20250115633-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | Invion Limited (AU) | 2025-04-10 | — | — | US | disclosed |
| EP-4436972-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW Cho Group Limited (HK) | 2024-10-02 | — | — | EP | disclosed |
| EP-4436971-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW Cho Group Limited (HK) | 2024-10-02 | — | — | EP | disclosed |
| CN-118679165-A | Photodynamic therapy and diagnosis | RMW曹氏集团有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118679164-A | Photodynamic therapy and diagnosis | RMW曹氏集团有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024115524-A1 | PORPHYRIN AND PHOSPHONIUM-PORPHYRIN BASED COMPOUNDS FOR PHOTODYNAMIC THERAPY AND DIAGNOSTICS | RMW CHO GROUP LIMITED (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2023094679-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| US-20190091245-A1 | Neuroprotection by mitochondria-targeted metformin | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| WO-2018193116-A1 | AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTICANCER AGENTS | NOVINTUM BIOTECHNOLOGY GMBH (CH) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018193126-A1 | AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTIBACTERIAL AGENTS | NOVINTUM BIOTECHNOLOGY GMBH (CH) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018193117-A1 | AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTICANCER AGENTS | NOVINTUM BIOTECHNOLOGY GMBH (CH) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018119207-A1 | SYNERGISTIC INIHIBITION OF TUMOR CELL PROLIFERATION INDUCED BY COMBINED TREATMENT OF METFORMIN COMPOUNDS AND IRON CHELATORS | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-9956233-B2 | Neuroprotection by mitochondria-targeted metformin | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170275313-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2017-09-28 | — | — | US | disclosed |
| EP-3179994-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | The Medical College of Wisconsin, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170106006-A1 | Neuroprotection by Mitochondria-Targeted Metformin | AIX-MARSEILLE UNIVERSITE (FR) | 2017-04-20 | — | — | US | disclosed |
| WO-2016025725-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275313-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | TFAM, MFN2, MT-ND5 | HIF1A 828/4885HRH1 4791/4885HTR2A 2753/4885 |
| US-20250115633-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | TPD52L2, CPNE4, CCNE2 | HIF1A 1063/4885HRH1 2705/4885HTR2A 3764/4885 |
| US-20170106006-A1 | Neuroprotection by Mitochondria-Targeted Metformin | NLN, MFN2, TFAM | HIF1A 380/4885HRH1 4569/4885HTR2A 983/4885 |
| US-20260035504-A1 | POLYMER AND USE THEREOF | CCNT1, C1S, CCNA1 | HIF1A 1833/4885HRH1 3887/4885HTR2A 4455/4885 |
| US-20250177533-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | PPOX, PPIF, ALAD | HIF1A 700/4885HRH1 4025/4885HTR2A 3831/4885 |
| US-20190091245-A1 | Neuroprotection by mitochondria-targeted metformin | NLN, MFN2, TFAM | HIF1A 380/4885HRH1 4569/4885HTR2A 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.